Project Grant K08HL179476
Award Date 8/15/25
Completion Date 7/31/30
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $190,998 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant will fund a research project titled "Understanding Pulmonary Fibrosis Through the Integration of Complex Occupational and Environmental Exposure Assessments (PF-OEM)." The project aims to use epidemiological tools to...
- This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...
- This federal Project Grant award of $248,999.00 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Virginia Commonwealth University (VCU) to support research on the role of the mechanoreceptor Piezo2 in regulating cellular metabolism and driving the progression of idiopathic pulmonary fibrosis (IPF). The project aims to characterize how Piezo2 mediates metabolic adaptations in lung fibroblasts in response to increased matrix...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $175,392 to the University of California, Los Angeles (UCLA) to support the research of Dr. Adam J. Brownstein, a pulmonary and critical care physician. The goal of this 5-year award is to enable Dr. Brownstein to establish himself as an independent investigator in patient-oriented research on pulmonary hypertension associated with pulmonary fibrosis (PF-PH)....
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $233,250 to the University of North Carolina at Chapel Hill (UNC-CH) to investigate the role of lipid metabolism in lung macrophage activity and phenotypes during acute lung injury. The project aims to understand how changes in lipid metabolism alter the function of lung macrophages during influenza A virus infection, which can lead to lung inflammation...